MAPLIGHT THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL FOR ML-007/PAC, UNDER DEVELOPMENT FOR SCHIZOPHRENIA AND ALZHEIMER’S DISEASE PSYCHOSIS

Posted on by

Study to evaluate safety and tolerability of extended-release fixed dose combination ML-007/PAC with precision-matched release kinetics in advance of planned Phase 2 clinical trials ML-007/PAC dosing regimens to be assessed in healthy non-elderly and elderly adults SAN FRANCISCO and…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.